IL-23 and Th17 Disease in Inflammatory Arthritis

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

(2016) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

An update on biomarkers in axial spondyloarthritis

(2016) Klára Prajzlerová et al.   AUTOIMMUNITY REVIEWS

Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review

(2016) Andrea Sukhov et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells

(2016) Renu Jain et al.   IMMUNITY

Role of interleukin-23 as a biomarker in rheumatoid arthritis patients and its correlation with disease activity

(2016) Doaa S.E. Zaky et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis

(2015) Smriti K Raychaudhuri et al.   CLINICAL RHEUMATOLOGY

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysregulated Serum IL-23 and SIRT1 Activity in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis

(2015) Daniel Wendling et al.   PLoS One

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

(2014) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

The IL-23/IL-17 axis in psoriatic arthritis

(2014) Erika Suzuki et al.   AUTOIMMUNITY REVIEWS

Cellular sources of IL-17 in psoriasis: a paradigm shift?

(2014) Romy R. M. C. Keijsers et al.   EXPERIMENTAL DERMATOLOGY

Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy

(2014) D. R. Jadon et al.   JOURNAL OF RHEUMATOLOGY

IL-23 Dependent and Independent Stages of Experimental Arthritis: No Clinical Effect of Therapeutic IL-23p19 Inhibition in Collagen-induced Arthritis

(2013) Ferry Cornelissen et al.   PLoS One

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

Functional role of IL-22 in psoriatic arthritis

(2012) Anupam Mitra et al.   ARTHRITIS RESEARCH & THERAPY

Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features

(2012) Raquel Celis et al.   ARTHRITIS RESEARCH & THERAPY

IL-17 receptor and its functional significance in psoriatic arthritis

(2011) Siba P. Raychaudhuri et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response

(2011) Heiner Appel et al.   ARTHRITIS RESEARCH & THERAPY

Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese

(2010) S. I. Davidson et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis

(2010) Yang Mei et al.   CLINICAL RHEUMATOLOGY

Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci

(2010) John D Reveille et al.   NATURE GENETICS

Development and function of TH17 cells in health and disease

(2009) Jennifer Louten et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: A novel mechanism of osteoclastogenesis by IL-17

(2009) Toru Yago et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes

(2009) Michael Goldberg et al.   MOLECULAR IMMUNOLOGY